Purchase Order HHSN272201700581P

The Defense Health Agency awarded a $11.6 million delivery order against its Medical Product Research and Development master IDIQ contract to PPD Development LP. This cost-plus-fixed-fee order is to provide clinical monitoring services for a Phase 2B proof of concept study being conducted in South Africa. The study aims to develop an HIV vaccine that meets the requirements of the U.S. Military. Performance will take place in South Africa over a five year period concluding in October 2022. No set...

This is a delivery order issued against the Homeland Defense and Security Technical Area Tasks (HD TATs) indefinite-delivery indefinite-quantity (IDIQ) contract, which is held by the U.S. Air Force Materiel Command. The $12,284,540.00 contract was awarded to Battelle Memorial Institute, a non-profit research and development organization, to support the Joint Vaccine Acquisitions Program's advanced filovirus vaccine development and continued medical countermeasures research. The contract involves...

The Department of the Army Medical Command awarded a $359,747 firm-fixed-price delivery order contract to PPD Development LP, a global contract research organization, for HIV vaccine market research. The contract is not set aside and is part of the Medical Product Research and Development Indefinite Delivery Contract (IDC) vehicle. PPD has extensive experience as a prime contractor and subcontractor providing clinical trial, research, regulatory, and other support services to federal agencies...

This federal contract award is for Protocol Development (base) and Protocol Implementation (options 1-6) services related to a Phase II clinical trial (Protocol 14-0112) to evaluate the safety, reactogenicity, and immunogenicity of the M-001 influenza A/H7N9 vaccine in healthy volunteers. The award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, under the Vaccine and Treatment Evaluation Units...

This is a $27,321,246 cost-plus-fixed-fee contract awarded by the U.S. Agency for International Development (USAID) to Path, a global nonprofit organization, for the "Innovations in Malaria Vaccine Development (IMV)" program. The contract aims to support novel and innovative approaches to malaria vaccine development, encompassing preclinical development through proof-of-principle clinical studies to motivate advanced development of a deployable, effective malaria vaccine. Key...

This is a Cost Plus Fixed Fee delivery order contract awarded by the Defense Health Agency to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp, to perform research and development in support of the U.S. Army Medical Materiel Development Activity (USAMMDA). The contract is for a Phase I, multi-center, randomized, double-blind, placebo-controlled study to assess the long-term ophthalmic safety of tafenoquine versus placebo. The potential value of the contract is $24,238,920.68,...

This is a $2,983,502.00 cost-plus-fixed-fee delivery order awarded to Rho Federal Systems Division Inc., a for-profit organization, by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the Department of Health and Human Services (HHS). The contract is for the Integrated Safety Summary Report of Clinical Studies Assessing Safety of Influenza Vaccines Administered with AS03 or MF59 Adjuvant. This order is part of a larger $250 million IDIQ...

This federal contract award is for the Fors Marsh Group LLC to provide social norming services for a pediatric vaccines campaign on behalf of the Office of Logistics and Acquisition Operations, which is a civilian agency. The contract has a ceiling value of $15,099,660.58 and is a Delivery Order under the Public Information and Communications Services II (PICS II) indefinite delivery vehicle. It has a period of performance through June 15, 2025. The contract does not utilize a set-aside. Fors...

This is a delivery order awarded to Technical Resources International, Inc. (TRI) by the Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) for the CLINICAL MONITORING INITIATIVE (CMI) VACCINE RESEARCH CENTER (VRC) 325 MOSAIC QUADRIVALENT INFLUENZA VACCINE project. The order is part of the VRC Clinical Monitoring Initiative 2017-2024 indefinite delivery/indefinite quantity (IDIQ) contract and has a potential...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $116,384 delivery order contract to The Johns Hopkins University. This follows a previous Phase I clinical study of a recombinant live attenuated tetravalent dengue virus vaccine. The Johns Hopkins University will conduct long-term follow up of previously enrolled subjects to further evaluate safety and immunogenicity. Two subcontracts were awarded in support of this work, including $117K to the...